Solventum (SOLV) Projected to Post Quarterly Earnings on Thursday

Solventum (NYSE:SOLV) is expected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Solventum to post earnings of $1.50 per share and revenue of $1.9613 billion for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Solventum Trading Up 1.6%

Shares of SOLV stock opened at $74.94 on Thursday. The business has a 50-day moving average of $79.61 and a 200 day moving average of $76.15. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20. The stock has a market capitalization of $13.00 billion, a PE ratio of 8.63, a P/E/G ratio of 6.77 and a beta of 0.35.

Solventum declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Solventum

Several large investors have recently modified their holdings of the stock. United Services Automobile Association purchased a new position in Solventum in the 1st quarter worth about $239,000. Woodline Partners LP boosted its holdings in shares of Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after acquiring an additional 3,377 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP raised its holdings in shares of Solventum by 5.8% during the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after purchasing an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Solventum during the second quarter valued at approximately $766,000.

Analyst Ratings Changes

Several research analysts have commented on the stock. Piper Sandler restated an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Tuesday, December 2nd. Stifel Nicolaus raised their price objective on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Mizuho set a $100.00 target price on Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Solventum presently has a consensus rating of “Hold” and an average price target of $90.83.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.